Edison Issues Research Outlook on Tissue Regenix (TRX)

Thursday, July 28, 2016 Research News J E 4

LONDON, July 28, 2016 /PRNewswire/ --

Tissue Regenix's (TRX) investment story is built on dCELL, a versatile regenerative medical technology, and its potential across the subsectors: wound care, orthopaedics and cardiac implants. Orthopaedics holds significant promise as the family of dCELL OrthoPure grafts is targeted at high-growth global markets where there are few effective alternatives. We have updated our sum-of-the-parts valuation model to Ģ338m, a slight reduction due to revised product timeline launches, costs and revenue forecasts.

     (Logo: )

We have revisited a number of our key valuation assumptions to reflect the clarity on launch timeframes, associated costs and updated revenue guidance. Our DCF valuation has reduced to Ģ338m (vs Ģ380m) or 44.4p (vs 50p) per share. According to our model, the current price gives a free option on wound care, the most commercially advanced division, and does not reflect the full pipeline potential, which could ultimately be an acquisition target as a whole or by division.  

Click here to view the full report.

All reports published by Edison are available to download free of charge from its website

About Edison: Edison is an international equity research firm with a team of over 110 analysts, investment and roadshow professionals and works with both large and smaller capitalised companies, blue chip institutional investors, wealth managers, private equity and corporate finance houses to support their capital markets activity. Edison provides services to more than 420 retained corporate and investor clients from offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information please contact: 

Dr. Linda Pomeroy, Edison Investment Research , +44-(0)20-3077-5738

Contact details: Learn more at and connect with Edison on:   LinkedIn: Twitter: YouTube: Google+:

SOURCE Edison Investment Research



You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Journal of Urology Publishes Results of Exact Imag...
Elsevier Launches Mobile-first, Personalized Learn...